Phage Therapy Market Size
| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 1.24 Billion |
| Market Size (2030) | USD 1.51 Billion |
| CAGR (2025 - 2030) | 3.99% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Phage Therapy Market Analysis
The Phage Therapy Market size is estimated at USD 1.24 billion in 2025, and is expected to reach USD 1.51 billion by 2030, at a CAGR of 3.99% during the forecast period (2025-2030).
The increasing prevalence of infectious diseases, growing research and development activities, and government initiatives to incorporate phage therapies are expected to expand the market over the forecast period.
The rising prevalence of infectious diseases, notably those resistant to conventional antibiotics, drives increased interest and investment in alternative therapeutic solutions. Phage therapy is increasingly recognized as an innovative solution within the healthcare market. Bacteriophages, or phages, are specialized viruses developed to target bacterial infections. These phages effectively eliminate harmful bacteria upon administration while preserving beneficial bacterial populations. For instance, according to an article published byMDPI in February 2023, phage therapy provides a formal alternative for treating infections caused by both antibiotic-sensitive and antibiotic-resistant bacteria with minimal toxicity to patients. With the increasing prevalence of infectious diseases and the limitations of traditional antibiotics, the phage therapy market is experiencing robust growth. This approach leverages live, bioengineered phages and their biological products, often integrated with chemical antibiotics, to effectively address bacterial infections.
Moreover, the increasing utilization of phage therapy in research and development (R&D) is a significant catalyst for market growth. As the exploration of phages' potential advances, businesses are identifying new applications and driving technological improvements. For instance, as per the article published by ScienceDirect in January 2023, the United Kingdom evaluated compassionate-use phage therapy requests through the National Health Service. In the United States, the FDA’s Office of Vaccines Research and Review (OVRR), within the Center for Biologics Evaluation and Research (CBER), oversees the clinical development of phages. The OVRR is fully equipped to regulate and ensure phage manufacturing operations' safety, purity, potency, and consistency.
Additionally, the government is focusing on strategic funding to support establishing and advancing clinical trials for phage therapy. This includes providing grants, infrastructure, and regulatory assistance to researchers. By facilitating these clinical trials, governments are collecting essential data on phage therapy's safety, efficacy, and potential benefits. For instance, the University of California, San Diego, in July 2023, stated that an NIH-sponsored early-stage phage therapy clinical trial is underway to evaluate the commercial potential and therapeutic efficacy of bacteriophage therapy in adults with cystic fibrosis (CF) who have Pseudomonas aeruginosa (P. aeruginosa) in their lungs. The trial aimed to determine the safety of the phage therapy and its ability to reduce the bacterial load in the lungs of the volunteers. In conclusion, Government investment in phage therapy is crucial to mitigate the business risks posed by the rising challenge of antibiotic resistance. By providing the necessary support, governments can significantly contribute to the growth and success of the phage therapy market, offering a promising solution to this global health challenge.
Due to the aforementioned factors, such as the increasing prevalence of infectious diseases, growing research and development activities, and government-promoting phage therapies for clinical trials.
However, the strict regulatory guidelines will significantly hinder their adoption in the forecast period.
Phage Therapy Market Trends
Pseudomonas Aeruginosa Segment is Expected to Hold a Significant Share in the Market Over the Forecast Period.
Pseudomonas aeruginosa, a Gram-negative rod-shaped bacterium, commonly infects plants, animals, and humans. Renowned for its adaptability, it flourishes in diverse environments, from soil and water to medical equipment. Particularly infamous in healthcare settings, P. aeruginosa targets patients with compromised immune systems, including those suffering from severe burns, cancer, or cystic fibrosis. The bacterium can instigate severe infections in various body parts, notably the blood, lungs (leading to pneumonia), and urinary tract.
Phage therapy, an emerging alternative to conventional antibiotics, is attracting attention for its precision in targeting harmful bacteria while preserving beneficial microorganisms. The increasing prevalence of multi-drug resistant (MDR) P. aeruginosa, a significant pathogen responsible for severe infections, is driving the demand for phage therapy. For instance, as per the article published by ELSEIVER published in March 2024, phage therapy presents a viable alternative to antibiotics for combating multidrug-resistant P. aeruginosa. Additionally, advancements in phage therapy against P. aeruginosa include using wild-type phages, genetically modified phages, phage cocktails, and combining phages with antibiotics, targeting both planktonic and biofilm forms of the bacteria.
According to the same source, wild-type phages can be used directly or undergo a training or engineering process to enhance their therapeutic properties. Furthermore, employing monophages or phage cocktails can improve the efficacy of phage therapy and reduce the risk of developing phage resistance. Hence, developing phage cocktails that target multiple strains of P. aeruginosa will boost market potential in the forecast period.
Additionally, researchers continue to refine in vivo infection models and generate compelling data, and the potential for phage therapy to become a valuable tool in combating P. aeruginosa infections appears increasingly promising. Researchers rely on in vivo infection models to assess the real-world efficacy of phage therapy targeting P. aeruginosa. For instance, the article published in BMC in February 2024, in an in vivo infection model utilizing a pan-resistant P. aeruginosa, phage therapy exhibits substantial therapeutic potential, effectively eradicating the infection from the blood, kidneys, and spleen. Therefore, in vivo infection models play a critical role in driving the growth of the phage therapy market by providing valuable insights into the efficacy, safety, and optimal use of phage therapy.
In conclusion, the segment's growth rise over the studied period due to the growing adoption of phage therapy in Pseudomonas aeruginosa as an alternative treatment option and researchers focusing on in vivo infection models related to P. aeruginosa.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
North America's market growth is driven by factors such as the increasing cases of infectious diseases such as UTIs, influenza, tuberculosis, and hepatitis B, and manufacturers increasing focus on activities such as agreements like partnerships, mergers, acquisitions, and investments, and healthcare infrastructure to support phage therapies for antibiotic-resistant infections.
As infectious diseases such as urinary tract infections and chronic wounds increase globally, the demand for effective treatments intensifies. Phage therapy is emerging as a solution for infections that resist conventional antibiotics. For instance, according to the article published in PubMed in September 2023, the increasing antibiotic resistance and the limited availability of effective treatments have intensified interest in alternative therapies for UTIs, particularly bacteriophage (phage) therapy. Phages are more effective than antibiotics in treating biofilms associated with UTIs. Therefore, the rising incidence of antibiotic-resistant UTIs, coupled with the distinct benefits of phage therapy, like its ability to target specific bacteria and disrupt biofilms, are propelling the expansion of the phage therapy market over the forecast period.
Additionally, in May 2024, extensive research and development (R&D) activities, fueled by university investments, are leading to the discovery of new phages and their innovative therapeutic applications. This accelerates the development and market introduction of new treatments. For instance, in May 2024, up to CAD 1.5 million (USD 1.08 million) will be available to support bacteriophage therapy initiatives across Canada 2024. The University of Toronto focused on controlling antibiotic-resistant bacteria through phages. These applications must address all aspects of One Health, including human and animal health, agriculture, food safety, and environmental considerations. Hence, universities' growing investments in phage therapy are propelling market growth. These investments accelerate R&D, nurture collaborations, elevate scientific expertise, grant access to cutting-edge technologies, and facilitate knowledge sharing.
Furthermore, manufacturers are propelling the growth of the phage therapy market by making significant investments and agreements. For instance, in July 2023, Armata Pharmaceuticals, Inc. secured a USD 25 million financing agreement from Innoviva, Inc. Innoviva, a company specializing in the development, commercialization, and financial management of biopharmaceuticals, provided this funding to advance Armata's pipeline of therapeutic phage candidates. These candidates include APPA02 and APSA02, which target infections caused by Pseudomonas aeruginosa and Staphylococcus aureus, respectively.
Similarly, in June 2023, Adaptive Phage Therapeutics secured a USD 12 million investment from funds managed by Deerfield Management and the AMR Action Fund, aiming to advance its cutting-edge phage therapy platform.
Therefore, owing to the aforementioned factors, such as the increasing cases of infectious diseases such as UTIs and manufacturers' increasing focus on activities such as funding, investments, and agreement, the market is expected to witness significant growth in the region.
Phage Therapy Industry Overview
The phage therapy market is moderately fragmented due to companies operating globally and regionally. Major players in the market are focused on product launches, approval, and advancements to expand their presence in the global market. The competitive landscape includes analyzing a few international and local companies that hold market shares and are well known, including Armata Pharmaceuticals, Inc., BiomX Inc, Eligo Bioscience, Intralytix, Inc., iNtODEWorld, and others.
Phage Therapy Market Leaders
-
Armata Pharmaceuticals, Inc.
-
BiomX Inc
-
Eligo Bioscience
-
Intralytix, Inc.
-
iNtODEWorld
- *Disclaimer: Major Players sorted in no particular order
Phage Therapy Market News
- March 2024: BiomX Inc. and Adaptive Phage Therapeutics, Inc. signed a merger agreement. BiomX, a clinical-stage company, focuses on the research and development of natural and engineered phage therapies targeting specific pathogenic bacteria.
- January 2024: Technophage reveled the successful dosing of the first patient in a pivotal clinical trial. The trial aims to assess the efficacy of TP-102 in treating diabetic foot ulcers caused by Staphylococcus aureus, Pseudomonas, and Acinetobacter baumannii. This Phase 2b trial is a double-blinded, randomized, placebo-controlled, multicenter study designed to evaluate both the safety and efficacy of TP-102 in patients with Diabetic Foot Infections.
Phage Therapy Industry Segmentation
As per the scope of the report, phage therapy employs bacteriophages to combat bacterial infections. These phages are adept at pinpointing and eliminating harmful bacteria, presenting a promising substitute for traditional antibiotics. This targeted approach safeguards beneficial bacteria and curtails potential side effects. The primary cell culture market is segmented by targeted bacteria, mode of administration, application, disease indication, and geography. By targeting bacteria, the market is segmented into Escherichia coli, Staphylococcus aureus, Streptococcus, Pseudomonas aeruginosa, Salmonella, and Other Bacteria. By mode of administration, the market is segmented into oral, topical, and injectable. By application, the market is segmented into infectious diseases, antibacterial resistance, biofilm infections, veterinary applications, and others. By disease indication, the market is segmented into urinary tract infections, chronic otitis, dental extraction, chronic ulcerative colitis, bone infection, wound and skin infections, cystic fibrosis, and others. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.
| By Targeted Bacteria | Escherichia coli | ||
| Staphylococcus aureus | |||
| Streptococcus | |||
| Pseudomonas aeruginosa | |||
| Salmonella | |||
| Other Bacteria | |||
| By Mode of Administration | Oral | ||
| Topical | |||
| Injectable | |||
| By Application | Infectious Diseses | ||
| Antibacterial Resistance | |||
| Biofilm Infecions | |||
| Veterinary Applications | |||
| Others | |||
| By Disease Indication | Urinary Tract Infections | ||
| Chronic Otitis | |||
| Dental Extraction | |||
| Chronic Ulcerative Colitis | |||
| Bone Infection | |||
| Wound and Skin Infections | |||
| Cystic Fibrosis | |||
| Others | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
| Escherichia coli |
| Staphylococcus aureus |
| Streptococcus |
| Pseudomonas aeruginosa |
| Salmonella |
| Other Bacteria |
| Oral |
| Topical |
| Injectable |
| Infectious Diseses |
| Antibacterial Resistance |
| Biofilm Infecions |
| Veterinary Applications |
| Others |
| Urinary Tract Infections |
| Chronic Otitis |
| Dental Extraction |
| Chronic Ulcerative Colitis |
| Bone Infection |
| Wound and Skin Infections |
| Cystic Fibrosis |
| Others |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
Phage Therapy Market Research FAQs
How big is the Phage Therapy Market?
The Phage Therapy Market size is expected to reach USD 1.24 billion in 2025 and grow at a CAGR of 3.99% to reach USD 1.51 billion by 2030.
What is the current Phage Therapy Market size?
In 2025, the Phage Therapy Market size is expected to reach USD 1.24 billion.
Who are the key players in Phage Therapy Market?
Armata Pharmaceuticals, Inc., BiomX Inc, Eligo Bioscience, Intralytix, Inc. and iNtODEWorld are the major companies operating in the Phage Therapy Market.
Which is the fastest growing region in Phage Therapy Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Phage Therapy Market?
In 2025, the North America accounts for the largest market share in Phage Therapy Market.
What years does this Phage Therapy Market cover, and what was the market size in 2024?
In 2024, the Phage Therapy Market size was estimated at USD 1.19 billion. The report covers the Phage Therapy Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Phage Therapy Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
